CN106458935B - 用于聚(adp-核糖)聚合酶-1(parp-1)的放射性标记示踪物，其方法和用途 - Google Patents

用于聚(adp-核糖)聚合酶-1(parp-1)的放射性标记示踪物，其方法和用途 Download PDF

Info

Publication number
CN106458935B
CN106458935B CN201580011735.7A CN201580011735A CN106458935B CN 106458935 B CN106458935 B CN 106458935B CN 201580011735 A CN201580011735 A CN 201580011735A CN 106458935 B CN106458935 B CN 106458935B
Authority
CN
China
Prior art keywords
parp
compound
tumour
mouse
pet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580011735.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106458935A (zh
Inventor
罗伯特·马赫
褚文华
周东
洛伦·米歇尔
戴尔芬·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of CN106458935A publication Critical patent/CN106458935A/zh
Application granted granted Critical
Publication of CN106458935B publication Critical patent/CN106458935B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201580011735.7A 2014-01-05 2015-01-05 用于聚(adp-核糖)聚合酶-1(parp-1)的放射性标记示踪物，其方法和用途 Active CN106458935B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461923759P 2014-01-05 2014-01-05
US61/923,759 2014-01-05
PCT/US2015/010129 WO2015103526A1 (en) 2014-01-05 2015-01-05 Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor

Publications (2)

Publication Number Publication Date
CN106458935A CN106458935A (zh) 2017-02-22
CN106458935B true CN106458935B (zh) 2019-05-28

Family

ID=53494075

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580011735.7A Active CN106458935B (zh) 2014-01-05 2015-01-05 用于聚(adp-核糖)聚合酶-1(parp-1)的放射性标记示踪物，其方法和用途

Country Status (7)

Country Link
US (2) US9993570B2 (OSRAM)
EP (2) EP3089965B1 (OSRAM)
JP (2) JP6407303B2 (OSRAM)
CN (1) CN106458935B (OSRAM)
CA (1) CA2935857C (OSRAM)
ES (1) ES2700348T3 (OSRAM)
WO (1) WO2015103526A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018183354A1 (en) 2017-03-27 2018-10-04 Tesaro, Inc. Niraparib compositions
EP3630287B1 (en) * 2017-05-24 2025-12-10 The Trustees Of The University Of Pennsylvania Radiolabeled and fluorescent parp inhibitors for imaging and radiotherapy
EP3687505A1 (en) * 2017-09-26 2020-08-05 Tesaro Inc. Niraparib formulations
CN117180277A (zh) * 2023-08-04 2023-12-08 中国辐射防护研究院 一种核素标记的靶向探针及其制备方法和应用
CN117586270B (zh) * 2023-11-07 2025-09-23 北京脑重大疾病研究院 放射性2，7，9a-三氮杂苯并[cd]天青-6（7H）酮衍生物及其制备方法和应用
CN120247879A (zh) * 2024-01-02 2025-07-04 南京亘泰医药技术有限公司 一种parp1和ulk1双靶点抑制剂及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1331682A (zh) * 1998-11-03 2002-01-16 巴斯福股份公司 取代的2－苯基苯并咪唑类,其制备和用途
CN1384835A (zh) * 1999-08-31 2002-12-11 阿古龙制药有限公司 聚(adp－核糖)聚合酶的三环抑制剂
CN101084020A (zh) * 2004-12-22 2007-12-05 哈默史密斯网上成像有限公司 放射性标记方法
US20090068105A1 (en) * 2006-08-29 2009-03-12 Washington University In St. Louis Isatin analogues and uses therefor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50031B (sr) 1999-01-11 2008-11-28 Agouron Pharmaceuticals Inc., Triciklični inhibitori poli(adp-riboza)polimeraza
HU0301154D0 (en) * 2003-04-28 2003-07-28 Hideg Kalman Dr Pharmaceutical composition
BRPI0719123A2 (pt) 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
US8506927B2 (en) * 2011-01-05 2013-08-13 Washington University Pegylated fluorobenzamide analogues, their synthesis and use in diagnostic imaging
WO2014037340A1 (de) * 2012-09-05 2014-03-13 Bayer Cropscience Ag Verwendung substituierter 2-amidobenzimidazole, 2-amidobenzoxazole und 2-amidobenzothiazole oder deren salze als wirkstoffe gegen abiotischen pflanzenstress

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1331682A (zh) * 1998-11-03 2002-01-16 巴斯福股份公司 取代的2－苯基苯并咪唑类,其制备和用途
CN1384835A (zh) * 1999-08-31 2002-12-11 阿古龙制药有限公司 聚(adp－核糖)聚合酶的三环抑制剂
CN101084020A (zh) * 2004-12-22 2007-12-05 哈默史密斯网上成像有限公司 放射性标记方法
US20090068105A1 (en) * 2006-08-29 2009-03-12 Washington University In St. Louis Isatin analogues and uses therefor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
[18F]Fluoroalkyl Agents: Synthesis, Reactivity and Application for Development of PET Ligands in Molecular Imaging;Ming-Rong Zhang等;《Current Topics in Medicinal Chemistry》;20071231;第7卷(第18期);第1817-1828页 *
chemistry of beta-emitting compounds based on fluonine-18;Marie-Claire Lasne等;《TOP. CURR. CHEM.》;20021231;第222卷;第201-258页 *
Diagnostic Role of 18F-FECH-PET/CT Compared with;Mustafa Takesh等;《ISRN Oncology》;20121231;第2012卷;第1-12页 *
Resistance-Modifying Agents. 9.1 Synthesis and Biological Properties of Benzimidazole Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase;Alex W.White等;《J.Med.Chem.》;20001019;第43卷;第4084-4097页 *
Synthesis and In Vivo Imaging of a 18F–labeled PARP1 Inhibitor Using a Chemically Orthogonal Scavenger-Assisted High-Performance Mehtod;Thomas Reiner等;《Angew.Chem.Int.Ed.》;20111231;第59卷;第1922-1925页 *

Also Published As

Publication number Publication date
EP3089965A1 (en) 2016-11-09
US9993570B2 (en) 2018-06-12
EP3424909A1 (en) 2019-01-09
CN106458935A (zh) 2017-02-22
EP3089965B1 (en) 2018-08-29
JP2017505336A (ja) 2017-02-16
ES2700348T3 (es) 2019-02-15
EP3089965A4 (en) 2017-06-21
CA2935857C (en) 2020-12-15
CA2935857A1 (en) 2015-07-09
US20160339124A1 (en) 2016-11-24
WO2015103526A1 (en) 2015-07-09
JP6407303B2 (ja) 2018-10-17
US20180326100A1 (en) 2018-11-15
JP2019001820A (ja) 2019-01-10

Similar Documents

Publication Publication Date Title
CN106458935B (zh) 用于聚(adp-核糖)聚合酶-1(parp-1)的放射性标记示踪物，其方法和用途
Zhou et al. Synthesis,[18F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography
US6562319B2 (en) Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
JP7622113B2 (ja) Ｐｓｍａ阻害剤を含有する１８ｆ標識トリアゾール
Zhou et al. Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer
ES2821273T3 (es) Compuesto derivado de 2-(3-piridinil)-1H-bencimidazol y medicamento que lo contiene
Chen et al. Development of a highly-specific 18F-labeled irreversible positron emission tomography tracer for monoacylglycerol lipase mapping
Kwon et al. Novel multifunctional 18F-labelled PET tracer with prostate-specific membrane antigen-targeting and hypoxia-sensitive moieties
JP5085824B2 (ja) 低酸素の検出のために有用な化合物の製造
Kiritsis et al. Synthesis and preclinical evaluation of rhenium and technetium-99m “4+ 1” mixed-ligand complexes bearing quinazoline derivatives as potential EGFR imaging agents
Kumar et al. In vivo comparison of N-11CH3 vs O-11CH3 radiolabeled microtubule targeted PET ligands
JP2007505101A (ja) 放射性標識されたアニリノキナゾリン型化合物ならびに放射線画像化および放射線治療におけるその使用
US8753605B2 (en) Imaging probes, methods of making imaging probes, and methods of imaging
TW202513043A (zh) 丹磺醯胺修飾的psma靶向化合物及其製備方法和應用
Selivanova et al. Synthesis and pharmacological evaluation of 11C-labeled piperazine derivative as a PET probe for sigma-2 receptor imaging
Class et al. Patent application title: Radiolabeled Tracers for Poly (ADP-RIBOSE) Polymerase-1 (PARP-1), Methods and Uses Therefor
Zhang et al. Design, synthesis and evaluation of 18F-labeled bradykinin B1 receptor-targeting small molecules for PET imaging
US20240174608A1 (en) Compounds for brain imaging
HK1231057B (en) Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
HK1231057A1 (en) Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
US20190224346A1 (en) Radiotracers for imaging er-positive breast cancer
CN118164957A (zh) 一种靶向成纤维细胞活化蛋白显像剂
Bauwens et al. Radioiodinated Phenylalkyl Malonic Acid Derivatives as pH-S nsitive SPECT
KR20070022190A (ko) 방사성 표식 아닐리노키나졸린 및 방사선 촬상 및 방사선 치료에 있어서의 그 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant